KRAS and neoplasm: Notably, SIAIS562055 monotherapy inhibited MIA PaCa-2/R tumor growth by 76.3% (P < 0.001) and demonstrated even greater antitumor efficacy, with a TGI of 100.5%, when combined with the KRAS inhibitor MRTX849 (Fig. 4E).